Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren’s Syndrome
Table 1
Clinical and laboratory characteristics of primary Sjogren’s syndrome and sicca patients.
Features
Sjogren’s syndrome ()
Sicca ()
value
Age at diagnosis, years
56.7 ± 1.32
58.0 ± 2.66
0.651
Sex, female (%)
68 (98.6)
21 (95.5)
0.427
BMI (kg/m2)
21.9 ± 0.34
22.5 ± 0.63
0.356
Disease duration, years
8.7 ± 0.78
5.7 ± 1.09
Anti-Ro (SSA), (%)
63 (91.3)
0 (0.0)
<
Anti-La (SSB), (%)
43 (62.3)
0 (0.0)
<
Antinuclear antibody, (%)
60 (87.0)
3 (13.6)
<
Rheumatoid factor, (%)
37/64 (57.8)
7 (31.8)
ESR (mm/hr)
26.6 ± 2.50
11.5 ± 1.64
<
CRP (mg/dL)
0.24 ± 0.06
0.13 ± 0.10
0.365
25(OH)-D3 (ng/mL)
22.0 ± 1.32
28.0 ± 2.69
BAFF (pg/mL)
1543 ± 141
1200 ± 182
0.225
β2 microglobulin (mg/L)
1.57 ± 0.08
1.19 ± 0.08
Extraglandular involvement (%)
35 (50.7)
0
ESSDAI
1.5 ± 0.17
0
Data are presented as mean ± SEM for continuous data and number (percentage) for categorical variables. BMI = body mass index; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; BAFF = B cell activation of the TNF family; ESSDAI = EULAR Sjogren’s syndrome disease activity index; .
